Conference Call with Syngene International Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Syngene International announced Q3FY25 results Reported revenue from operations up by 11% to Rs 944 crore. Reported PAT (after exceptional items) up by 18% to Rs 131 crore. Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International, said: “Syngene’s third quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter. Our Discovery Services division saw the initial “China+1” pilot projects, with large and midsize pharma companies, starting to convert into longer term contracts. This underscores Syngene’s ability to build strong partnerships through a combination of great science and high operating and quality standards. Now, our focus is on further business development and building the sales pipeline. The quarter also saw positive momentum in our CDMO division led by biologics. Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected.” Deepak Jain, Chief Financial Officer, Syngene International Limited said: “The third quarter performance delivered year-on-year growth. Reported profit after tax (before exceptional items) for the quarter grew by 14% supported by operating EBITDA margins that came in at 30.1%, up from 27.1% in the previous year. We continued to focus on investing in digital initiatives, new technologies and commercial capabilities to drive growth.” Result PDF